All problems

For UK HealthTech companies

Your pipeline stalls because the right clinicians never see your solution

Senior clinical decision-makers in the NHS and private sector are effectively insulated from cold outreach. Without a warm introduction or a credible clinical champion, most healthtech companies wait months, or years, for the right conversation.

Two minutes. Solva follows up with specific market access options.

  • Healthtech sales teams struggling to secure initial meetings with key clinical stakeholders
  • Products failing to gain traction despite clear clinical value due to lack of internal advocacy
  • Prolonged sales cycles and stalled pilot projects without a clinical champion to drive adoption
  • Missed opportunities for co-development or clinical validation with leading UK private healthcare institutions
  • Inefficient resource allocation within sales and marketing teams
  • Stalled product development due to lack of clinical feedback and co-creation opportunities
  • Significant revenue loss due to prolonged sales cycles and missed deal closures
  • Increased customer acquisition costs due to reliance on less effective outreach methods
  • Delayed access for patients to potentially beneficial healthtech innovations
  • Slower adoption of solutions that could improve clinical workflows and patient safety
  • Perception of the healthtech company as lacking credibility or clinical understanding
  • Difficulty attracting top talent due to a perceived inability to penetrate key markets

Warm introductions are 5-10x more effective at driving meaningful conversations than cold outreach (Draftboard, 2024)

Source: https://www.draftboard.com/blog/the-power-of-warm-intros-why-cold-outreach-is-fading-in-b2b-sales

Frequently asked questions

Why does this problem persist?

Access to senior clinicians and clinical decision-makers in the NHS and private sector is a genuine barrier. Cold outreach rarely works. The pathway is almost always through a warm introduction, a clinical network, or a conference relationship.

What is the cost of leaving it unaddressed?

No verified UK data available

This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.

Related problems

Solvable.Health© 2026

This information is for educational purposes only and does not constitute professional advice.